Tong-Ming Fu | CSO infectious Diseases
IGM Infectious Disease

Dr. Tong-Ming Fu is currently the CSO for Infectious Diseases at IGM Biosciences, INC. He spent over two decades at Merck Research Laboratories, Merck and Co., Inc., where he contributed to many novel vaccine programs, including adenovirus vector HIV-1 vaccines and influenza M2 peptide-conjugate vaccine, and conducted research to understand immune mechanisms of novel adjuvants and immune modulations by PD-1 blocking mAbs. Notably, he initiated and led the research efforts on a novel Merck cytomegalovirus vaccine V160, which has advanced to a Phase 2 for efficacy evaluation. After his tenure at Merck, he served as the head of Sanofi Vaccine Research North America unit and led multiple vaccines and biologics programs including respiratory syncytial virus, influenza virus, SARS-CoV2, and chlamydia, and novel vaccine technology platforms including mRNA vaccines and human antibodies. He is also an adjunct professor at the University of Texas Health Science Center at Houston and has published extensively on vaccine and biologics discoveries and immune responses.